Belaris develops implantable stents that combine mechanical support with localized biologic therapy to treat fibrosis, not merely relieve obstruction. By delivering anti‑scarring medication directly at the site of repeat scar formation, their devices aim to improve healing quality and reduce the need for repeated interventions. The approach targets conditions where scar tissue narrows critical bodily pathways, offering a more durable solution than conventional stents.
Funding
Funding not disclosed
Founders
Product
Problem
Fibrosis generates persistent scar tissue that can progressively narrow essential bodily pathways, leading to recurrent blockages even after conventional interventions.
Solution
Belaris creates implantable stents that integrate mechanical support with localized delivery of cell‑free biologic therapeutics. The device maintains lumen patency while releasing anti‑scarring agents directly at the site where fibrosis recurs, aiming to improve tissue healing quality and reduce the need for repeat procedures. By embedding controlled‑release technology into the stent structure, Belaris provides a combined structural and pharmacologic solution that targets the underlying fibrotic process rather than merely relieving obstruction.
Target Audience
Primary customers are medical device manufacturers and healthcare providers treating fibrosis‑related conditions such as vascular restenosis, biliary strictures, and airway stenosis.
Features
- Stent platform that offers radial support to keep ducts, vessels, or other conduits open
- Integrated reservoir and release matrix for cell‑free biologic agents that inhibit scar formation
- Controlled, site‑specific drug elution kinetics designed to match the timeline of fibrotic remodeling
- Compatibility with standard implantation techniques and delivery systems
- Modular design allowing adaptation of therapeutic payloads for different fibrosis‑driven indications